- Home
- ZENV vs CELU Comparison
ZENV vs CELU Comparison
Compare ZENV & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- CELU
- Stock Information
- Founded
- ZENV 2005
- CELU 2016
- Country
- ZENV Brazil
- CELU United States
- Employees
- ZENV N/A
- CELU N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- CELU Health Care
- Exchange
- ZENV Nasdaq
- CELU Nasdaq
- Market Cap
- ZENV 70.8M
- CELU 56.9M
- IPO Year
- ZENV 2021
- CELU N/A
- Fundamental
- Price
- ZENV $1.28
- CELU $1.68
- Analyst Decision
- ZENV
- CELU Strong Buy
- Analyst Count
- ZENV 0
- CELU 1
- Target Price
- ZENV N/A
- CELU $6.00
- AVG Volume (30 Days)
- ZENV 21.8K
- CELU 66.6K
- Earning Date
- ZENV 11-14-2025
- CELU 11-14-2025
- Dividend Yield
- ZENV N/A
- CELU N/A
- EPS Growth
- ZENV N/A
- CELU N/A
- EPS
- ZENV N/A
- CELU N/A
- Revenue
- ZENV $201,426,369.00
- CELU $40,578,000.00
- Revenue This Year
- ZENV $12.75
- CELU N/A
- Revenue Next Year
- ZENV N/A
- CELU $76.00
- P/E Ratio
- ZENV N/A
- CELU N/A
- Revenue Growth
- ZENV 24.80
- CELU N/A
- 52 Week Low
- ZENV $1.02
- CELU $1.00
- 52 Week High
- ZENV $3.03
- CELU $4.35
- Technical
- Relative Strength Index (RSI)
- ZENV 46.03
- CELU 42.55
- Support Level
- ZENV $1.29
- CELU $1.62
- Resistance Level
- ZENV $1.46
- CELU $1.83
- Average True Range (ATR)
- ZENV 0.11
- CELU 0.16
- MACD
- ZENV 0.01
- CELU 0.01
- Stochastic Oscillator
- ZENV 57.14
- CELU 45.00
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.